Amber Gottman
Family · Palmyra, MONPI 1831589944
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $907, more than ten times the $39 reported in 2021.
Across 105 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$321
- AbbVie$286
- Novartis$181
- Amgen$133
- Lilly USA, LLC$121
- EMD Serono, Inc.$104
- plus $755 from 16 others
What the payments were for
- Food & beverage$1,900100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $321 |
| AbbVie | 25 | $286 |
| Novartis | 10 | $181 |
| Amgen | 7 | $133 |
| Lilly USA, LLC | 6 | $121 |
| EMD Serono, Inc. | 2 | $104 |
| Novo Nordisk | 7 | $102 |
| Otsuka America Pharmaceutical, Inc. | 4 | $102 |
| Teva Pharmaceuticals USA, Inc. | 3 | $77 |
| Boehringer Ingelheim | 4 | $73 |
| Exact Sciences | 3 | $62 |
| Axsome Therapeutics, Inc. | 4 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $36 |
| Pfizer | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Harmony Biosciences LLC | 2 | $30 |
| Boston Scientific | 1 | $21 |
| Gilead | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
How this compares
$1,900 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 16 | $15,850 |
| Duloxetine Hcl | 34 | $2,075 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $1,102 |
| Nebivolol Hcl | 11 | $905 |
| Pantoprazole Sodium | 61 | $804 |
| Doxycycline Hyclate | 67 | $686 |
| Amlodipine Besylate | 124 | $614 |
| Gabapentin | 44 | $580 |
| Potassium Chloride | 32 | $579 |
| Metoprolol Succinate | 27 | $497 |
| Omeprazole | 56 | $472 |
| Levothyroxine Sodium | 59 | $461 |
| Atorvastatin Calcium | 88 | $432 |
| Lisinopril | 61 | $407 |
| Cefdinir | 25 | $359 |
Paid to pharmacies, not to this prescriber.
Other family in Palmyra
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
- Jennifer GriggColumbia$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.